Christopher L D McMillan

12PUBLICATIONS
55CO-AUTHORS
Nanotoxicology, health and safetyGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Composite and hybrid materialsAnimal protection (incl. pests and pathogens)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jan 28, 2026
Booster Immunisation with Skin-Patch-Delivered Unadjuvanted SARS-CoV-2 Spike Protein Vaccine Is Safe and Immunogenic in Healthy Adults.

Christopher L D McMillan, David A Muller, Germain J P Fernando

|Jan 21, 2023
Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern.

Mahali S Morgan, Kexin Yan, Thuy T Le

|May 28, 2022
Absence of Anti-RBD Antibodies in SARS-CoV-2 Infected or Naive Individuals Prior to Vaccination with CoronaVac Leads to Short Protection of Only Four Months Duration.

Camille F de Oliveira, Walter F F Neto, Carla P da Silva

|Apr 23, 2022
Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern.

Christopher L D McMillan, Armira Azuar, Jovin J Y Choo

|Nov 27, 2021
Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch.

Jovin J Y Choo, Christopher L D McMillan, Germain J P Fernando

|Nov 09, 2021
Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses.

Christopher L D McMillan, Stacey T M Cheung, Naphak Modhiran

Pageof 2

Frequent Collaborators

6 joint publications

David A Muller

6 joint publications

Naphak Modhiran

5 joint publications

Paul R Young

4 joint publications

Daniel Watterson